Aclaris Therapeutics (ACRS) Non-Current Debt (2018 - 2021)

Aclaris Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $10.7 million for Q2 2021.

• On a quarterly basis, Non-Current Debt rose 1.49% year-over-year to $10.7 million in Q2 2021; TTM through Jun 2021 was $10.7 million, a 1.49% increase from a year earlier, with the FY2020 full-year figure at $10.7 million, changed N/A from the prior year.
• Non-Current Debt steadied at $10.7 million in Q2 2021 per ACRS's latest filing, from $10.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $29.9 million in Q3 2019 and bottomed at $10.6 million in Q1 2020.
• The 4-year median for Non-Current Debt is $10.7 million (2021), against an average of $18.4 million.
• Across the five-year window, Non-Current Debt sank 64.67% in 2020 and increased 1.49% in 2021, its largest moves.
• Year by year, Non-Current Debt stood at $29.9 million in 2018, then increased by 0.05% to $29.9 million in 2019, then tumbled by 64.41% to $10.7 million in 2020, then increased by 0.73% to $10.7 million in 2021.
• Per Business Quant, the three latest ACRS Non-Current Debt figures stand at $10.7 million (Q2 2021), $10.7 million (Q1 2021), and $10.7 million (Q4 2020).